New Patients can experience EVERSENSE E3 for as low as $99† (Learn More)

Eversense is the only long-term CGM system with 6 months of real-time glucose readings and only 2 sensors per year. Because you have life to manage, not just diabetes.

Get Started

How Eversense Works

Eversense gives you real-time glucose readings through a small sensor that’s placed just under the skin of your upper arm by an Eversense Inserter. The smart transmitter sits above the sensor, sending glucose data to your app.

Get More With the Only Long-Term CGM

More Convenience

1 sensor for 6 months of real-time glucose readings

More Flexibility

More Flexibility

Easy-on, easy-off smart transmitter allows you to take a break when needed*

More Comfort

More Comfort

Mild, silicone-based adhesives, changed daily

More Confidence in CGM Data

More Confidence in CGM Data2

Exceptional accuracy, notably during high and low events

Components of the Eversense CGM System

Eversense diabetes CGM system sensor.

Sensor

The sensor is inserted by an Eversense Inserter in the upper arm and continuously measures glucose for up to 6 months.

View Sensor >
Eversense CGM smart transmitter device.

Smart Transmitter

Worn over the sensor, the transmitter wirelessly sends data to user’s mobile device; is removable** and rechargeable and provides unique on-body vibe alerts.

View Transmitter >
Woman holding a cell phone with Eversense diabetes information.

Mobile Application

Displays and updates real-time glucose readings every 5 minutes with intuitive graphical design to show if you are in or out of range. Remote real-time monitoring capability - up to 5 people.†

View App >

The Only Implantable Sensor For Long-Term Wear

While all CGM systems use transcutaneous sensors that are inserted into the skin and last 7-14 days, the Eversense sensor is inserted completely under the skin. The Eversense CGM system lasts up to 6 months — eliminating the hassle and discomfort of frequent sensor insertions. Simply put, it makes managing your diabetes so much easier.

 

Thanks! We've got your info.

A Diabetes Therapy Associate will be in touch shortly, but if you want to reach out sooner, please call 1-945-221-9068.

To help expedite benefits verification, please have your doctor and insurance information handy.

We will attempt to reach you by phone first, and will send a text and email as well. The call may be displayed on your phone as "Eversense CGM". However, it will come from a number you are unfamiliar with, so be sure to check your voicemail box. The email from our representative will come from an @ascensia.com email address. If you haven’t received any email communications from our team within a few days, please check the spam folder in your email account.

Looking forward to getting in touch with you!

Thanks! We've got your info.

Unfortunately, based on the insulin therapy regimen or insurance information you provided, you may not be eligible for Eversense E3 CGM. In order to qualify, you must be on multiple daily doses of insulin.

If you do not have insurance, or if your insurance carrier does not cover Eversense E3 CGM, our PASS Program may help make Eversense E3 more accessible.

If you have any questions, please reach out to 1-844-736-7348.

A general error occurred. Please try again later.
Get Started with Eversense

If you're on insulin, you might greatly benefit from Eversense. After completing the form below, an Eversense representative will be in touch to discuss eligibility, coverage and next steps.

Diabetes Type*
Number of Daily Insulin Injections*

By clicking ‘submit’ you confirm you are over 18, and agree to Ascensia, or our trusted partner, collecting and using your health-related information to check your insurance coverage and eligibility for Eversense. An Ascensia Diabetes Care representative will be in touch about getting started, usually by phone or text message.

We would also like to use your information to tell you about Ascensia products, offers, and events that help you to manage your diabetes. You can click below to agree to hearing from Ascensia Diabetes Care (ADC), or a service provider on ADC’s behalf:

You can opt out any time e.g. by replying STOP to a text, or calling ADC at 1-844-736-7348* For more details of how we use your information, please see our Privacy Policy.

*Standard text messaging and/or calling charges may apply. For more details, see our website Conditions of Use. Consent to these messages is not a requirement for purchase.

  

  

  

Coverage

Learn more about insurance coverage and eligibility

VIEW COVERAGE
Woman using her phone to research coverage for an implantable CGM.

FAQ

Search our most commonly asked questions for quick answers.

VIEW FAQS
Woman views cell phone to read about Eversense CGM FAQs.

Connecting the Dots

See how Eversense changed Troy’s life in this mini-documentary style video, which was produced for Ascensia by BBC StoryWorks Commercial Productions.

† The offers above only apply to the cost of the sensor and transmitter or sensor only. They do not cover the cost of the insertion procedure. Limitations and Restrictions may apply. Ascensia Diabetes Care reserves the right to change or terminate this program at any time without notice. The program benefit is capped per transaction. There may be instances in which patient out-of-pocket costs exceed what is detailed in INTRO and ONGOING offers.
* Up to 6 months
**There is no glucose data generated when the transmitter is removed
***The opinions expressed belong solely to the individual. This information provides general information only. It is not intended to be used as medical advice, diagnosis or treatment and should not replace the advice of a Health Care Provider
1. Deiss D., et al. (2020). Real-World Safety of an Implantable Continuous Glucose Sensor Over Multiple Cycles of Use: A Post-Market Registry Study. Diabetes Technol & Ther, 22(1);48-52. DOI: 10.1089/dia.2019.0159.
2. Eversense E3 User Guide.

 

Disclaimer

The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For safety information click here.

Eversense, Eversense E3 Continuous Glucose Monitoring and the Eversense logo are trademarks of Senseonics, Incorporated. Ascensia, and the Ascensia Diabetes Care logo are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.

Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.

Get Started